Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
40.98 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Ultragenyx Pharmaceutical Inc. |
Symbool | RARE |
Munteenheid | USD |
Prijs | 40.98 |
Beurswaarde | 3,784,269,414 |
Dividendpercentage | 0% |
52-weken bereik | 37.02 - 60.37 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Emil D. Kakkis M.D., Ph.D. |
Website | https://www.ultragenyx.com |
An error occurred while fetching data.
Over Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)